News
HRTX
3.050
-1.61%
-0.050
Weekly Report: what happened at HRTX last week (0715-0719)?
Weekly Report · 4d ago
HERON THERAPEUTICS ANNOUNCES THE INCLUSION OF ZYNRELEF® AS A QUALIFYING PRODUCT UNDER THE PROPOSED 2025 NON-OPIOID POLICY FOR PAIN RELIEF UNDER THE OPPS AND THE ASC PAYMENT SYSTEM
Reuters · 07/15 12:00
Weekly Report: what happened at HRTX last week (0708-0712)?
Weekly Report · 07/15 10:56
New Strong Buy Stocks for July 11th
NASDAQ · 07/11 11:06
Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View
NASDAQ · 07/10 16:57
Weekly Report: what happened at HRTX last week (0701-0705)?
Weekly Report · 07/08 10:58
Noteworthy Tuesday Option Activity: HRTX, HOG, PANW
NASDAQ · 07/02 19:47
Heron Therapeutics Down over 19%, On Pace for Largest Percent Decrease Since May 2023 -- Data Talk
Dow Jones · 07/02 19:19
Heron Therapeutics’ ZYNRELEF Review Date Set by FDA
TipRanks · 07/02 13:21
Heron Therapeutics announces acceptance of PAS application for dual-acting anesthetic
Healthcare Heron Therapeutics announces acceptance of PAS application for dual-acting anesthetic. FDA has assigned a PDUFA date of September 23, 2024 for the company's supplement application for Zynrelef extended-release solution VAN.
Seeking Alpha · 07/02 13:18
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
NASDAQ · 07/02 12:43
Heron Therapeutics Announces The FDA Acknowledged The Receipt Of The Company's Prior Approval Supplement Application For ZYNRELEF
The FDA has assigned a PDUFA goal date of September 23, 2024 for ZYNRELEF's extended-release solution VAN. If approved, the VAN is expected to be available for use in the fourth quarter of this year. The VAN has the potential to simplify aseptic preparation.
Benzinga · 07/02 12:02
*Heron Therapeutics Announces FDA Acceptance of Prior Approval Supplement Application for ZYNRELEF Vial Access Needle >HRTX
Dow Jones · 07/02 12:02
HERON THERAPEUTICS INC - U.S. FOOD AND DRUG ADMINISTRATION ("FDA") ASSIGNED A PRESCRIPTION DRUG USER FEE ACT ("PDUFA") GOAL DATE OF SEPTEMBER 23, 2024
Reuters · 07/02 12:00
Weekly Report: what happened at HRTX last week (0624-0628)?
Weekly Report · 07/01 10:58
Heron Therapeutics: Opioid-Free Surgical Pain Relief Maven With Low Cash Reserves
Seeking Alpha · 06/27 21:42
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
NASDAQ · 06/26 16:57
Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?
NASDAQ · 06/25 10:30
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
NASDAQ · 06/24 14:19
Weekly Report: what happened at HRTX last week (0617-0621)?
Weekly Report · 06/24 11:05
More
Webull provides a variety of real-time HRTX stock news. You can receive the latest news about Heron Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.